Zoloft (Sertraline)
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stress Disorders, Post-Traumatic
Conditions
Stress Disorders, Post-Traumatic
Trial Timeline
Nov 1, 2002 → Jul 1, 2007
NCT ID
NCT00150306About Zoloft (Sertraline)
Zoloft (Sertraline) is a phase 3 stage product being developed by Pfizer for Stress Disorders, Post-Traumatic. The current trial status is terminated. This product is registered under clinical trial identifier NCT00150306. Target conditions include Stress Disorders, Post-Traumatic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00150306 | Phase 3 | Terminated |
Competing Products
20 competing products in Stress Disorders, Post-Traumatic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + placebo | Eli Lilly | Phase 2 | 52 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| Thermal stress and performance without a pre-cooling protocol | Petros Pharmaceuticals | Pre-clinical | 15 |
| solifenacin | Astellas Pharma | Approved | 85 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| duloxetine + Placebo | Eli Lilly | Phase 2 | 52 |
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| duloxetine HCl | Eli Lilly | Approved | 85 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine hydrochloride + placebo | Eli Lilly | Approved | 85 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |